Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

IND Documentation for CRISPR-Cas9 Therapeutics

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

IND Documentation for CRISPR-Cas9 Therapeutics

IND Documentation for CRISPR-Cas9 Therapeutics: CMC and Regulatory Strategy

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in Regulatory CMC Documentation.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Executive Summary

Preparing a Chemistry, Manufacturing, and Controls (CMC) data package for a CRISPR-Cas9 based therapeutic requires a multi-faceted analytical strategy. These systems involve distinct characterization of the guide RNA (gRNA), the nuclease payload (e.g., Cas9 mRNA or ribonucleoprotein), and the delivery vehicle, often a lipid nanoparticle (LNP). A successful Investigational New Drug (IND) submission to the FDA hinges on robust documentation demonstrating control over each component and the final assembled product. This includes rigorous identity, purity, and potency assays, alongside comprehensive data on non-target tissue biodistribution and potential off-target editing events.

Frequently Asked Questions

What are the primary CMC documentation challenges for CRISPR-Cas9 IND submissions?

The main challenge is managing the complexity of a multi-component system. Regulators expect detailed characterization and release specifications for the gRNA, the Cas9 nuclease, and the LNP delivery system independently, as well as for the final formulated product. Demonstrating consistent manufacturing and analytical control across all parts is a frequent point of regulatory scrutiny.

How does Franklin Biolabs ensure its facilities meet GxP requirements for gene editing programs?

Our operations are conducted within a GxP framework designed for next-generation therapies. Our >100,000 sq ft of specialized laboratory and housing space provides the controlled environments necessary for reproducible IND-enabling studies. You can see our facilities here:. This infrastructure supports the generation of high-integrity data suitable for FDA review.

What is the typical timeline for preparing IND-enabling studies for an LNP-delivered CRISPR therapeutic?

An integrated approach that aligns CMC development with preclinical toxicology can position a program for IND submission within 18-24 months. This timeline depends on factors like target indication and the maturity of the analytical methods, but our model is built to minimize delays between manufacturing, analytical release, and the initiation of pivotal safety studies.

Deconstructing the CRISPR-Cas9 Submission Package

A robust IND submission for a CRISPR-Cas9 therapeutic is built on a foundation of meticulous analytical data. Each component of the therapeutic system presents unique manufacturing and characterization hurdles that must be addressed in the CMC section of the filing.

The regulatory expectation is a clear demonstration of process control and product understanding. This involves developing and qualifying phase-appropriate assays that can reliably measure the quality attributes (CQAs) of each input material and the final drug product.

Key analytical domains for the submission package include:

  • Guide RNA (gRNA): Documentation must confirm sequence identity, integrity, purity (absence of truncated or incomplete sequences), and concentration.

  • Cas9 Nuclease (mRNA or RNP): For mRNA payloads, analytics focus on capping efficiency, poly(A) tail length, and integrity. For ribonucleoprotein (RNP) complexes, characterization of protein purity and gRNA-binding affinity is required.

  • Lipid Nanoparticle (LNP) Vehicle: Data must cover particle size, polydispersity, zeta potential, encapsulation efficiency of the payload, and the identity and purity of the constituent lipids.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

The Impact of Delivery System Innovation on CMC

Advances in non-viral delivery directly influence the scope of CMC documentation. For instance, the development of novel ionizable lipids to improve endosomal escape and enhance in vivo editing efficiency (PMID: 39856035) introduces new materials that require full characterization.

While these innovations can significantly improve therapeutic potency, they also necessitate a corresponding expansion of the analytical package to cover the stability and purity of the new excipients.

This is where an integrated program strategy becomes valuable. By developing the CMC and analytical plan in parallel with preclinical toxicology, potential risks associated with novel delivery systems can be identified and mitigated early. This prevents late-stage surprises that could delay an IND filing.

An Integrated Path to IND Readiness

Our approach coordinates CMC, analytics, and preclinical development into a single, coherent strategy. This model is designed to accelerate timelines for sponsors targeting the US FDA regulatory pathway. The track record of our core scientific leadership and principal scientists includes a 100% successful IND rate since 2019, a history of execution that predates the formal launch of Franklin Biolabs in 2024. This experience provides the proven intelligence needed to navigate the specific regulatory questions associated with gene editing platforms.

The entire process is supported by GxP-compliant environments and a deep understanding of what is required to move from candidate nomination to a successful IND submission.

For more information on our broader capabilities, please see our main services page.
Vector | CMC | Analytics Services

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities